Silenced Thyroid Gene CRABP1 Signals Aggressive Cancer Cells, Study Finds

Papillary thyroid carcinoma is the world’s most common thyroid malignancy, and for most patients it carries an excellent prognosis. Yet this apparent benignity hides a genuine clinical puzzle: a subset of tumors behaves aggressively, spreading to lymph nodes and defying the usual rule that early-stage thyroid cancer is an indolent disease. Surgeons and oncologists have long lacked reliable molecular tools to tell the two fates apart at diagnosis. Now a team at The Tenth Affiliated Hospital of Southern Medical University, working with collaborators in Jiangsu and Liaoning, China, reports that a single retinoid-binding protein, CRABP1, may help draw that line. Their study, published in Frontiers in Cell and Developmental Biology, links the loss of CRABP1 to an invasive malignant cell state, to methylation changes in tumor DNA, and to measurable shifts in migration and invasion in laboratory models.

The investigation began in the single-cell realm. Rather than grinding whole tumors into an averaged molecular signature, the researchers mined publicly available single-cell RNA sequencing data from 17 papillary thyroid carcinoma samples drawn from three independent public repositories. After rigorous quality control, they used a technique called Harmony to correct for the technical batch effects that arise when samples are processed in different laboratories, then annotated the tumor ecosystems cell by cell. This resolved the expected cast of characters: epithelial cells, fibroblasts, endothelial cells, pericytes, macrophages, T cells, NK cells, B cells, plasma cells, and rarer immune populations. The epithelial compartment, the seedbed of carcinoma itself, was then subdivided into ten subclusters for closer scrutiny.

Here the study deployed one of its most technically elegant moves: copy-number inference. Normal cells carry two copies of every chromosome, but cancer cells accumulate large-scale chromosomal gains and losses. Using the InferCNV pipeline, with macrophages serving as a genomically clean reference population, the team quantified these broad alterations in each individual epithelial cell. One subcluster, designated C6, showed copy-number disruption as severe as any malignant population, confirming its cancerous identity. Critically, this population also expressed high levels of CRABP1 while retaining classical epithelial markers such as CDH1, the gene encoding E-cadherin, and KRT19, a keratin characteristic of thyroid lining cells. In other words, CRABP1 did not mark an infiltrating stromal cell type; it marked a specific, bona fide malignant epithelial state.

Did that state matter clinically? To find out, the researchers turned to The Cancer Genome Atlas thyroid carcinoma cohort, the largest publicly available bulk transcriptomic dataset for the disease. Differential-expression analysis using DESeq2, with shrinkage of fold-change estimates to guard against noise, revealed that tumors with lymph-node metastasis expressed significantly less CRABP1 than node-negative tumors. CRABP1 levels also varied across pathological T categories, a measure of primary tumor size and local extent, and were lower in tumors than in adjacent healthy thyroid tissue. An exploratory gene set enrichment analysis in an external 157-patient cohort added texture: CRABP1-low tumors showed reduced enrichment for focal adhesion and tight junction pathways and elevated oxidative phosphorylation signatures. The authors are careful to frame these as unadjusted observational associations, but the direction is consistent and biologically coherent.

Correlation is cheap, so the team moved into the wet laboratory. Among seven thyroid cancer cell lines screened by quantitative PCR, HTC-C3, an anaplastic-derived line, expressed the most CRABP1, while FTC-238, isolated from a metastatic follicular carcinoma, expressed comparatively little. These became the complementary test beds. Silencing CRABP1 with small interfering RNAs in HTC-C3 cells made them visibly more mobile: in Transwell assays, cells must squeeze through 8-micrometer pores, and with a Matrigel coating mimicking basement membrane, they must also digest their way through. CRABP1-depleted cells crossed more of both barriers. Conversely, forcing CRABP1 overexpression in FTC-238 cells suppressed migration and invasion. The molecular fingerprint accompanied the behavior: CRABP1 knockdown lowered E-cadherin and raised N-cadherin, Vimentin, and Snail, a classic epithelial-mesenchymal transition signature, while overexpression reversed the pattern.

The in vivo evidence followed. The researchers injected control or CRABP1-depleted HTC-C3 cells into the flanks of immunodeficient BALB/c nude mice and tracked tumor growth for 24 days. Tumors lacking CRABP1 grew faster and ended heavier, and their tissue showed higher Ki-67 staining, a marker of cell proliferation, along with the same E-cadherin-low, mesenchymal-high gene expression shift seen in culture. CRABP1 depletion, in short, pushed thyroid cancer cells toward a more proliferative, more invasive, more mesenchymal identity inside a living animal, not just on plastic.

What silences CRABP1 in the first place? The team’s epigenetic analysis points toward DNA methylation, the chemical addition of methyl groups to cytosines that can dampen gene activity. Using the UALCAN portal on TCGA methylation arrays, they found that aggregated methylation of promoter-region probes near the CRABP1 transcription start site was higher in primary tumors than in normal thyroid, in both node-positive and node-negative disease. Probe-level mapping sharpened the picture: one CpG site, cg02276974, sits inside intron 2 of the CRABP1 gene on the south shore of a CpG island, and in 505 matched tumor samples its methylation was weakly but significantly inversely correlated with CRABP1 RNA abundance, with a Pearson correlation of minus 0.2069. The authors are explicit that this single site explains only about four percent of expression variation and cannot be declared a causal regulatory element, but it is a concrete, testable lead.

To probe that lead pharmacologically, they applied decitabine, a demethylating agent that inhibits DNA methyltransferases and is already approved in oncology for myelodysplastic syndromes. In both cell models, decitabine reduced migration, invasion, and Vimentin fluorescence intensity, and the strongest suppression appeared in CRABP1-overexpressing cells treated with the drug. In the xenograft setting, decitabine was associated with lower tumor weight and volume in the CRABP1-depleted background, alongside reduced Ki-67 and shifted EMT marker expression. Because decitabine acts genome-wide, these experiments establish a methylation-associated pharmacological context rather than proving that the drug specifically resurrects CRABP1 or unmethylates that particular intronic site. Notably, the animal design lacked a control-plus-decitabine arm, a limitation the authors candidly acknowledge.

The study also sketches the tumor’s social network. Using CellChat, a computational tool that predicts ligand-receptor crosstalk from transcriptomic data, the team found that CRABP1-positive malignant epithelial cells appeared poised to communicate with macrophage subpopulations through APP-CD74 and PPIA-BSG signaling axes. These predictions are hypotheses, not demonstrations of physical signaling, but they suggest that this malignant state may help sculpt its own inflammatory microenvironment, a question that now invites experimental testing with co-culture and spatial profiling approaches.

The implications ripple outward in several directions. Clinically, CRABP1 joins a growing list of markers that could eventually help separate tumors worth surgery from those suitable for active surveillance, an increasingly urgent distinction given evidence that a large fraction of diagnosed papillary thyroid carcinomas represent overdiagnosis. Scientifically, the work reframes a bulk-level gene finding as a single-cell state question, reminding researchers that a gene’s clinical signal may reflect the changing prevalence of a particular cell population within the tumor rather than uniform behavior across all cells. And pharmacologically, the decitabine results hint that demethylating therapy could blunt invasive phenotypes in methylation-driven contexts, though the bridge from nude mice to patients remains long and untested. The authors themselves draw careful boundaries: associations are associations, drug responses are drug responses, and no locus-specific epigenetic causality has been established. That restraint is precisely what makes the findings credible. What the study does deliver is a sharply defined malignant epithelial state, a plausible epigenetic handle on its regulation, and a concrete experimental agenda for turning CRABP1 from a molecular curiosity into a clinically useful signpost for thyroid cancer patients.

Subject of Research: CRABP1 downregulation and methylation in aggressive papillary thyroid carcinoma

Article Title: Methylation-associated downregulation of CRABP1 marks an aggressive malignant epithelial cell state in thyroid carcinoma

Article References: Fu, T., Li, Y., Huang, G., Hu, X., Luo, G., Wang, C., Wang, Y., Ding, Z., Zhou, J., & Li, Z. (2026). Methylation-associated downregulation of CRABP1 marks an aggressive malignant epithelial cell state in thyroid carcinoma. Frontiers in Cell and Developmental Biology, 14, Article 1974822. https://doi.org/10.3389/fcell.2026.1974822

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1974822

Keywords: CRABP1, papillary thyroid carcinoma, single-cell RNA sequencing, DNA methylation, decitabine, epithelial-mesenchymal transition, lymph node metastasis, copy number variation, TCGA, tumor microenvironment, retinoic acid signaling, cancer epigenetics